INBXInhibrx Biosciences, Inc.

1. Sep 8, 2026Updated Phase 2 Data for INBRX-106 in First-Line HNSCC On September 8, 2026, Inhibrx announced the primary endpoint results from the randomized and controlled Phase 2 portion of its HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab …Regulation FD disclosure · Form 8-K
2. Aug 13, 2026Inhibrx Reports Second Quarter 2026 Financial Results.Earnings release · press release
3. Jul 16, 2026On July 15, 2026, Inhibrx Biosciences, Inc. (the “Company”), Oxford Finance LLC as collateral agent (“Collateral Agent”), and the other lenders party thereto (the “Lenders”), entered into a second amendment (the “Second Amendment”) to the Loan and Security Agreement dated as of January 13, 2025, as amended by the …Material agreement entered · Form 8-K
4. Jun 15, 2026On June 15, 2026, the Company announced that the FDA has accepted for filing its BLA seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.Regulation FD disclosure · Form 8-K
5. May 14, 2026Inhibrx Reports First Quarter 2026 Financial Results.Earnings release · press release
6. May 11, 2026Inhibrx from time to time presents and/or distributes the presentation to the investment community during conferences and meetings to provide updates and summaries of its business.Regulation FD disclosure · Form 8-K
7. Apr 21, 2026Inhibrx from time to time presents and/or distributes the presentation to the investment community during conferences and meetings to provide updates and summaries of its business.Regulation FD disclosure · Form 8-K
8. Mar 19, 2026Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results.Earnings release · press release
9. Dec 16, 2025On December 16, 2025, Inhibrx announced (i) an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint …Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.